ves esta página sin formato por que esta hecha cumpliendo el estándar web CSS 2.
tú navegador no soporta este estándar, o tienes dicho soporte desactivado.
si estas en el primer caso, actualízate. merece mucho la pena.

MI PRIMERA BITACORA

Temas
  • Salud
  • <Septiembre 2018
    Lu Ma Mi Ju Vi Sa Do
              1 2
    3 4 5 6 7 8 9
    10 11 12 13 14 15 16
    17 18 19 20 21 22 23
    24 25 26 27 28 29 30
                 


    WWW http://prueba.blogalia.com

    Blogs informática médica
    Medical Informatics
    Julio Bonis MD

    Blogs mantenidos por médicos
    Adolescentes
    Consulta joven virtual
    Copensalud
    Diario de un residente de cardiologia de Valencia
    Diario de un médico del SAS
    El bisturí
    Endocitosis de red
    La Dama de las Artemias
    Lluisalcanyis.org
    Nuevos modelos de gestión
    Primablog
    Una de médicos
    Vigilando la gripe
    Bitácora de Webcalidad
    Vila-real, t´estime

    Blogs de Diario Medico
    Panorama desde el puente
    La Semeca en Guatemala
    Política de salud de la UE
    Salud pública en acción
    En los pasillos de la bioética
    La Oncología Médica al día
    Congreso AHA 2005
    La Oncología Médica al día
    Ahí viene la plaga
    La Jungla de Cristal
    Ahí viene la plaga
    Síndrome de abstinencia

    Blogs mantenidos por enfermeros
    Blog Maite Martínez Lao
    Jetlageando

    Blogs mantenidos por pacientes y usuarios
    Fibromialiadori
    Hepatitis C Iberica
    HOSPITAL DE LA RIBERA DE ALZIRA, LA VERGÜENZA

    Otros Blogs de Salud
    Avenir de la Santé

    Blogs "super"
    atalaya
    eCuaderno
    cosa humeda

    Blogs femeninos
    A contraluz
    Allyenna
    Benko
    Biblioteca de Babel
    Evasivas
    Chicaconfaldaroja
    Lapetiteclaudine
    Maria milonas
    Mi libro de arena
    Yolandax

    Blogs de políticos
    Ramón Basas PSC-PSOE
    Rosa Maria Bonàs i Pahissa ERC
    Miquel Bofill ERC
    Gustavo de Arístegui PP
    Rafael Estrella PSOE
    Francesc Ferrer i Gironés ERC
    Carlos González PSOE
    Esteban González Pons PP
    J J Ibarretxe PNV
    Miquel Iceta PSOE-PSC
    L Martinez Oblanca PP
    Manel Mas PSOE-PSC
    J L Moreno PP
    L Muñoz Santamaría PSOE-PSC
    Enric Nomdedéu BNV
    J Puig Cordón ERC
    Alicia Sánchez PP
    Maria San Gil PP
    Francisco Toledo
    J A Torres Mora PSOE
    Francisco Valverde PSOE

    TRANSLATE

    Blogalia

    Blogalia


    ©2003 jrnegre

    AVISO
    2018-09-05

    Dice Novartis tener la autorización de la EC para Kymriah

    Dice Novartis tener la autorización de la Comisión Europea para Kymriah, aunque en la página de la Ema, a día de hoy, aún aparece como pendiente.


    The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r pediatric B-cell ALL and r/r DLBCL.

    Novartis is the only company with an approved CAR-T cell therapy for pediatric r/r B-cell ALL and the first to receive approval in two distinct indications, both in the EU and the US


    El informe favorable estaría basado en los ensayos clínicos ELIANA para la recidiva de LLA en menores de 25 años:

    The EC approval of Kymriah in pediatric and young adult patients with r/r B-cell ALL is based on the pivotal Phase II ELIANA clinical trial, the first pediatric global CAR-T cell therapy registration study for Kymriah in children and young adults with r/r B-cell ALL. ELIANA was conducted in collaboration with the University of Pennsylvania and Children’s Hospital of Philadelphia, evaluating Kymriah in patients in 25 centers in the US, Canada, Australia, Japan, and in Europe, in Austria, Belgium, France, Germany, Italy, Norway and Spain. 

     In this Novartis-sponsored, global, multi-center study evaluating 75 patients infused with Kymriah with three or more months of follow-up, 81% of patients achieved overall remission (95% CI: 71% - 89%) with 80% of responders still in remission at 6 months. Sixty percent of patients achieved complete response (CR) and 21% of patients achieved CR with incomplete blood count recovery (CRi). Of those patients in remission, 100% had no minimal residual disease (MRD) detected in the bone marrow1. Overall survival (OS) was 90% at six months, and 76% at 12 months. Median OS was 19.1 months (95% CI: 15.2 - NE) in this difficult-to-treat patient population.


     y JULIET para los linfomas difusos de células B grandes en adultos:

    The EC approval of Kymriah in adult patients with r/r DLBCL is based on the pivotal Phase II JULIET clinical trial, the first multi-center global registration study for Kymriah in adult patients with r/r DLBCL. JULIET was conducted in collaboration with the University of Pennsylvania, and is the largest study examining a CAR-T therapy in DLBCL, enrolling patients from 27 sites in 10 countries across the US, Canada, Australia, Japan, and Europe in Austria, France, Germany, Italy, Norway and the Netherlands.

     In the JULIET trial, patients were infused in the inpatient and outpatient setting. In this Novartis-sponsored, global, multi-center study, among 93 evaluable patients who were followed for at least three months or discontinued earlier, Kymriah demonstrated an overall response rate (ORR) of 52% (95% confidence interval [CI], 41% - 62%), with 40% achieving a complete response (CR) and 12% achieving a partial response (PR). The relapse-free probability at 6 and 12 months was 68% and 65%, respectively; and the median duration of response was not reached at the time of data cut-off, indicating sustainability of response1. The OS rate at 12 months was 49% and median OS was 11.7 months among all infused patients (n=111) (95% CI, 6.6-NE).

    2018-09-05 21:26 | 0 Comentarios


    2018-09-01

    El NICE inglés y Yescarta

    Hace muy pocos días, el NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) inglés ha publicado un documento para pública consulta sobre la  efectiviad de Yescarta en su indicación solicitada: tratamiento de adultos con linfoma difuso de células B grandes o mediástinico primario con fracaso tras al menos dos líneas de tratamientos.


    Este documento concluye, de modo provisional:

     1 Recommendations 

    1.1 Axicabtagene ciloleucel is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory diffuse large Bcell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

     1.2 This recommendation is not intended to affect treatment with axicabtagene ciloleucel that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Why the committee made these recommendations

    Why the committee made these recommendations

     There is no standard treatment for relapsed or refractory diffuse large Bcell lymphoma or primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. Best supportive care is used and usually includes salvage chemotherapy. Evidence from a small, single-arm study suggests that people having axicabtagene ciloleucel have good response rates, overall survival and progression-free survival. But, there are no direct data comparing axicabtagene ciloleucel with salvage chemotherapy (referred to as best supportive care by the company). This means that the exact size of the benefit of axicabtagene ciloleucel compared with salvage chemotherapy is unknown. Axicabtagene ciloleucel meets NICE’s criteria to be considered a lifeextending treatment at the end of life. However, all the cost-effectiveness estimates are above the range normally considered to be a cost-effective use of NHS resources. Axicabtagene ciloleucel does not meet the criteria for inclusion in the Cancer Drugs Fund. Because of this, axicabtagene ciloleucel is not recommended.


    -----

    Cost-effectiveness results 

    The range of the cost-effectiveness estimates is wide and all are above £50,000 per QALY gained 


    3.23 The company’s deterministic base case showed that the incremental costeffectiveness ratio (ICER) for axicabtagene ciloleucel compared with salvage chemotherapy was over £50,000 per QALY gained. The exact ICER is commercial in confidence and cannot be reported here. The ERG made some changes to the company’s model to reflect its preferred basecase analysis, specifically: 




    These changes resulted in an ERG exploratory base-case ICER that was over £100,000 per QALY gained. The committee noted the wide range between the company’s and ERG’s base-case ICERs. It agreed that there was a high degree of uncertainty associated with both the company’s and ERG’s estimates because of the limitations in the data for the comparator and the immature survival data for axicabtagene ciloleucel. The committee concluded that based on the data and analyses presented to it, the cost-effectiveness estimates were all above £50,000 per QALY gained.


    2018-09-01 06:16 | 0 Comentarios


    2018-08-05

    Resultados del primer semestre de 2018 de MolMed

    MolMed ha presentado los resultados del primer semestre de 2018  y en dicho informe se puede leer en la página 33:
    Contrariamente alle previsioni, le vendite non sono ancora iniziate né in Italia né in Germania a causa delle difficoltà riscontrate nelle fasi iniziali della commercializzazione del prodotto. Tale situazione è al momento oggetto di un attento esame da parte di MolMed al fine di valutare le opportune azioni da intraprendere, anche in relazione a talune divergenze sorte in merito all’adempimento del contratto di commercializzazione stipulato con Dompé, i cui esiti ad oggi non sono prevedibili. 
    En la página 20:
     ricavi dal prodotto Zalmoxis ® pari a Euro 2.224 migliaia, derivanti dall’accordo di licenza e distribuzione di Zalmoxis® siglato in data 26 luglio 2017 con Dompé e alla vendita del prodotto in regime di fondo  Aifa
    El informe presenta una descripción amplísima de los riesgos financieros.
    A partir de informes anuales y trimestrales he reconstruido la serie de valores trimestrales que abajo se presenta en la gráfica. En el Q4-2017 hay valores "raros" como ventas negativas, pero no encuentro el error si lo hay.

     

     

     

    2018-08-05 22:17 | 0 Comentarios


    2018-07-26

    Resultados económicos de los CART en 2018

    En una entrada anterior, presentábamos el resultado económico de Kymriah en el primer trimestre de 2018.

     Los dos laboratorios titulares de las autorizaciones (Novartis y Gilead) han presentado los resultados del conjunto de la empresa y parciales de sus medicamentos correspondientes al Q2 de 2018. Presentamos abajo en una tabla el resumen de los datos con enlaces a las fuentes.

























































    Datos de ingresos generados por los CART autorizados durante
    2018 (millones de dólares)
    Q1 Q2 Q1+Q2
    Kymriah 12 16 28
    Yescarta 40 68 108

    Fuentes:

    datos de Kymriah: Q1 en Labiotech/ Goldman Sachs; Q2 web de Novartis

    datos sobre Yescarta (Q1 y Q2) en web de Gilead;

    2018-07-26 18:53 | 0 Comentarios


    2018-07-24

    UCART: no están autorizadas pero están en ello

    https://degenetica.blogspot.com/2018/07/ucart-no-estan-autorizadas-pero-estan.html


    Una vez en el mercado KYMRIAH y YESCARTA, autorizados por la FDA en agosto y octubre de 2017 respectivamente y por la EMA en Junio de 2018, a falta del informe favorable de la CE, el paso conceptualmente siguiente es la generalización del procedimiento en un doble sentido: linfocitos allogénicos que sirvan para tratar más tipos de tumores que los hematológicos (LLA y linfomas de celulas B grandes).

    En este proceso además de los aspectos científicos están los empresariales dado el enorme potencial económico que tendrá esta técnica cuando se mejore y autorice su puesta en el mercado. Ejemplos científico empresariales como Ari Belldegrun (urólogo, oncólogo, empresario de múltiples iniciativas: venta de Kite Pharma y puesta en marcha de Allogene Therapeutics, de momento) me parecen fomidables.

    En abril de 2018 se ha formalizado la constitución de Allogene Therapeutics con un acuerdo con Pfizer, como en diversos documentos manifiesta Allogene en su web :

    "As a result of the completed agreement, Allogene has received from Pfizer the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR T therapy that is being developed for treatment of CD19- expressing hematological malignancies. In partnership with Servier, UCART19 is initially being developed in acute lymphoblastic leukemia (ALL) and is currently in Phase 1. UCART19 utilizes TALEN® gene editing technology pioneered and owned by Cellectis."



    También habla de otros participantes en el acuerdo como Gilead, adquiriente de Kite en 2017:



    "Pfizer will continue to participate financially in the CAR T portfolio’s development through a 25 percent ownership stake in Allogene. Prior to the agreement’s completion, Gilead Sciences joined Allogene’s premier Series A investment consortium that already included TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer, and Pfizer, among others."

    El fundamento de las UCART sería la eliminación del fragmento de adn que codifica los receptores de los linfocitos T, según indican en el artículo FIRST-IN-HUMAN STUDY WITH UCART19, AN ALLOGENEIC ANTI-CD19 CAR T-CELL PRODUCT, IN HIGH RISK ADULT PATIENTS WITH CD19+ R/R B-CELL ALL: PRELIMINARY RESULTS OF CALM STUDY de presentación de resultados de UCART de Cellectis, Pfizer y Servier en el congreso de EBMT en Lisboa 2018:

    "UCART19 (anti-CD19 scFv- 41BB- CD3ζ) is a genetically modified CAR T-cell product manufactured from healthy donor cells, in which TRAC and CD52 genes have been knocked out to allow its administration in non-HLA matched patients."





    Imagen procedente de Phase I study of UCART19, an allogeneic anti-CD19 CAR T-cell product, in high risk adult patients with CD19+ relapsed/refractory (R/R) B-cell ALL: Preliminary results of phase I CALM study presentación de resultados de UCART19 en el congreso de la EHA en 2018.


    Un aspecto de interés es el acuerdo de Cellectics con MolMed para la fabricación de las células UCART.



    2018-07-24 09:00 | 0 Comentarios


    portada | subir

    Listed on BlogShares